In a nutshell This study investigated the effectiveness and safety of sacituzumab govitecan (Trodelvy; SG) compared to chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer (mTNBC). The data showed that SG significantly improved the survival outcomes of these patients compared to chemotherapy. Some background...
Read More
In a nutshell This study compared the real-world safety and effectiveness of the palbociclib (Ibrance) plus letrozole (Femara) versus letrozole alone in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-negative (HER2-) metastatic breast cancer (MBC). The data concluded that palbociclib in combination with...
Read More
In a nutshell This study aimed to compare the effectiveness and safety of endocrine therapy (ET) or chemotherapy (CT) before surgery in patients with invasive ductal carcinoma (IDC) of the breast that is hormone receptor (HR) positive (+) and human epidermal growth factor receptor 2 (ERBB2) negative (-). The study concluded CT before...
Read More
In a nutshell This article looked at several clinical trials to assess the safety of pembrolizumab (Keytruda) in patients with triple-negative breast cancer (TNBC). The authors found that pembrolizumab had an acceptable safety profile and was effective in treating all stages of TNBC. Some background Breast cancer (BC) is one of the most common...
Read More
In a nutshell This study investigated whether adding oral S-1 (Teysuno) to hormonal therapy improved outcomes in patients with estrogen receptor (ER)-positive and HER2-negative primary breast cancer (BC). The data showed that the combination of S-1 with hormonal therapy could be a potential treatment option for these patients. Some background...
Read More
In a nutshell This study aimed to investigate the combination of alpelisib (Piqray) and fulvestrant (Faslodex) in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor 2 (HER2) negative, advanced breast cancer (BC). This study concluded that this combination provided positive outcomes for...
Read More
In a nutshell This study was carried out to assess the use of radiotherapy (RT) after mastectomy (surgical removal of the breast) for triple-negative breast cancer (TNBC) that has spread to the lymph nodes. The authors found that RT after surgery was associated with improved survival in patients with larger tumors. Some background Triple-negative...
Read More
In a nutshell This study looked at the outcomes of older women with triple-negative breast cancer who received chemotherapy before or after local treatment. The data showed that chemotherapy can be considered in the treatment of these patients. Some background Triple-negative breast cancer (TNBC) is a subtype of breast cancer (BC) that tests...
Read More
In a nutshell This phase 2 clinical trial is evaluating the safety and effectiveness of targeted therapy TAS-120 (futibatinib) alone or in combination with fulvestrant (Faslodex) in patients with metastatic breast cancer (mBC). The main outcomes to be evaluated will be the response rate and survival without cancer worsening. The details Breast...
Read More
In a nutshell This study was carried out to examine the effectiveness of olaparib (Lynparza) for the treatment of metastatic breast cancer (MBC; cancer that has spread) with gene mutations (abnormalities). The authors found that this treatment was effective for patients with MBC with BRCA1/2 mutations. Some background Breast cancer (BC) is one of the...
Read More
In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced solid...
Read More
In a nutshell This study is looking to trial the addition of a new form of vaccine called a neoantigen vaccine in combination with nab–paclitaxel (Abraxane), duvalumab (Imfinzi), and tremelimumab (CP-675,206), in patients with metastatic triple-negative breast cancer (mTNBC). The main outcome that will be measured is survival without the...
Read More
